Radiofrequency Ablation of Breast Cancer: A Retrospective Study

Toshikazu Ito, Shoji Oura, Shinji Nagamine, Masato Takahashi, Naohito Yamamoto, Noboru Yamamichi, Mitsuharu Earashi, Hiroyoshi Doihara, Shigeru Imoto, Shoshu Mitsuyama, Kohei Akazawa

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Combination of ultrasound-guided RFA of breast cancer with concurrent sentinel lymph node biopsy could potentially become state-of-the-art breast-conservative therapy for early breast cancer. Purpose: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas. Methods: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis. Patients underwent a standard RFA procedure with ultrasound guidance and were followed up every 6 to 12 months. In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. Fisher exact or χ 2 test evaluated associations between clinicopathological factors and IBTR, and local recurrence-free survival was estimated using the Kaplan-Meier method. Results: RFA-related adverse events included local pain in 9 patients, skin burns in 15, and nipple retraction in 7. Patients were followed for a median of 50 months. IBTR was more frequently observed in patients with initial tumor sizes > 2 cm (3 of 30, 10%) than in those with initial tumors ≤ 2 cm (8 of 355, 2.3%; P =.015). IBTR-free rates 5 years after RFA were 97%, 94%, and 87% in patients with initial tumor sizes ≤ 1.0 cm, 1.1 to 2.0 cm, and > 2.0 cm, respectively. Conclusions: RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Further studies are needed to optimize the technique and evaluate its future role as local therapy.

Original languageEnglish
Pages (from-to)e495-e500
JournalClinical Breast Cancer
Volume18
Issue number4
DOIs
Publication statusPublished - Aug 2018

Keywords

  • Breast cancer
  • Ipsilateral breast tumor recurrence
  • Local therapy
  • Minimally invasive surgical procedures
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Radiofrequency Ablation of Breast Cancer: A Retrospective Study'. Together they form a unique fingerprint.

Cite this